EMA and FDA Establish Principles for AI Use in Drug Development

The European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) have jointly released a set of ten principles aimed at guiding the use of artificial intelligence (AI) in drug development. This initiative responds to the rapid integration of AI technologies within the biopharmaceutical sector, which is transforming processes from drug discovery to clinical trials and eventual market release.

These principles, detailed in a publicly available document, are designed to inform future regulatory guidance in both the United States and the European Union. They will also play a pivotal role in establishing international standards for AI applications in the pharmaceutical industry. According to the regulators, this framework provides “broad guidance on AI use in evidence generation and monitoring” across all stages of medicine development, from early research through to manufacturing and safety oversight.

Core Principles for Ethical AI Development

The first principle emphasizes that AI systems must be human-centric in their design and align with established ethical values. This means that developers must adopt a risk-based approach that considers the specific context in which the AI will be used. Additionally, compliance with current legal, ethical, technical, scientific, cybersecurity, and regulatory standards is essential.

A clear context of use must be established for each AI application, and the development process should include multidisciplinary expertise. Strict data governance and documentation controls are vital, particularly regarding privacy and the protection of sensitive information. This includes utilizing best practices in model and system design along with software engineering.

Before any AI system is permitted for use, it must undergo rigorous risk-based performance assessments. This will include testing human-AI interactions. Ongoing monitoring and periodic re-evaluation will also be critical to ensure that these systems continue to meet their intended purposes throughout their operational lifespan.

The regulators have also highlighted the necessity for AI technologies to communicate information in a manner that is “clear, accessible, and contextually relevant” to users and patients. This emphasis on transparency aims to enhance the understanding and trust in AI applications in healthcare settings.

Collaborative Efforts and Industry Impact

The release of these principles marks a significant step in enhancing cooperation between the EU and the US in the field of innovative medical technologies. Olivér Várhelyi, the European Commissioner for Health and Animal Welfare, stated, “The guiding principles of good AI practice in drug development are a first step of a renewed EU-US cooperation.” He underscored the importance of collaboration in maintaining a leading role in global innovation while prioritizing patient safety.

The surge in AI adoption within the biopharmaceutical industry is evident in the increasing number of partnerships between biopharma companies and AI specialists. Recent collaborations include Iktos working with both Servier and Pierre Fabre, Insilico Medicines partnering with Servier, and GSK collaborating with Noetik and Helix. Additionally, AstraZeneca has acquired Boston-based Modella AI to integrate its AI capabilities into its research and development operations.

As the landscape of drug development evolves with the integration of AI, these principles will serve as a foundation for ensuring that the technology is harnessed responsibly and ethically, ultimately benefiting patients and the healthcare system at large.